Factor B Inhibitors
1 drugsAbout Factor B
Factor B is a serine protease in the alternative pathway of the complement system, crucial for innate immunity. It amplifies the complement cascade, leading to pathogen opsonization and lysis, thus modulating immune responses.
Factor B is a compelling drug target due to its central role in the complement cascade, implicated in various diseases. Currently, there is no genetic evidence directly linking Factor B to specific diseases.
There is one FDA-approved drug, FABHALTA (Novartis), targeting Factor B with small molecule modality. It has three indications within the 'other' therapeutic area.
Top Factor B Drugs
Novartis is the only company with an approved Factor B-targeting drug.
Low competition presents a first-mover advantage but also highlights potential market risks.
Factor B Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Factor B, using small molecule modality.
The exclusive use of small molecules suggests an opportunity for novel modalities like antibodies or biologics.
Factor B Clinical Trials 13 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Factor B. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 4 | 1 | 1 | 2 | 50% |
| Phase 3 | 8 | 2 | 0 | 6 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Factor B Drug Approval Timeline (2023 - 2023)
The first and most recent drug approval for Factor B was FABHALTA in 2023.
Recent approval indicates growing interest, but a single approval suggests market is nascent and not yet saturated.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Factor B. A trial counts if an approved drug acting on Factor B is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.